Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.

Compounds, methods of use, and processes for making inhibitors of Complement Factor B are provided.

The disclosure features methods of analyzing a fluid extracted from a reservoir, the methods including introducing a first composition featuring a first complexing agent into a reservoir at a first location, extracting a fluid from the reservoir at a second location different from the first location, combining the fluid with a second composition featuring a concentration of a lanthanide ion to form a third composition featuring a concentration of a complex formed by the first complexing agent and the lanthanide ion, exposing a quantity of the complex to electromagnetic radiation for a first time period ending at a time t.sub.0, detecting fluorescence emission from the quantity of the complex for a second time period starting at a time t.sub.1>t.sub.0, where t.sub.1−t.sub.0 is greater than 2 microseconds, and determining information about a fluid flow path between the first location and the second location.

The present invention relates to a method for preparing the compound of formula IV, compound of formula XI, and acalabrutinib, a new generation of bruton tyrosine kinase (BTK) inhibitor. ##STR00001##

The present invention relates to a method for preparing the compound of formula IV, compound of formula XI, and acalabrutinib, a new generation of bruton tyrosine kinase (BTK) inhibitor. ##STR00001##

The present invention relates to an aryl amide compound of formula (I′), a pharmaceutical composition comprising same, a preparation method therefor, and the use thereof for preventing or treating tumor-related diseases or conditions.

##STR00001##

The present invention relates to an aryl amide compound of formula (I′), a pharmaceutical composition comprising same, a preparation method therefor, and the use thereof for preventing or treating tumor-related diseases or conditions.

##STR00001##

The present application provides solid forms and salts of a compound of Formula (I):

##STR00001##

pharmaceutical compositions thereof, methods of treating a disease or disorder associated with CDK2 using the same, and processes of preparing the compound of Formula (I) and the solid forms and salts.

Compounds of formula (I), wherein A, R, W.sup.1, W.sup.2, W.sup.3, W.sup.4, W.sup.5, W.sup.6, L, Q, R.sup.x and u have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease. ##STR00001##

Compounds of formula (I), wherein A, R, W.sup.1, W.sup.2, W.sup.3, W.sup.4, W.sup.5, W.sup.6, L, Q, R.sup.x and u have the meaning according to the claims, can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease. ##STR00001##